Based on the current evidence, we hypothesised that treatment naïve CML CD34+ cells possess a gene expression programme independent of the BCR-ABL1 TK, which allows them to persist following TKI treatment and that the components of this programme could be targeted to eradicate the leukaemic clone. This evidence concerns the gene ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive.